Daisy A. Robinton (born March 1987) is a molecular biologist, entrepreneur, lifestyle and fitness model, writer, and public speaker. She is the director of women's health at Cambrian Bio and the cofounder, CEO, and board director of Oviva Therapeutics,[1] a biotechnology company dedicated to broadening the study of female physiology, ovarian function, and menopause. For her work, she has been recognized by Forbes as one of their 30 under 30.[2]

Early life and education

Robinton grew up in Palo Alto, California. She went on to earn a Bachelor of Science in molecular, cell, and developmental biology in 2010 from the University of California, Los Angeles and a PhD from Harvard University in human biology and translational medicine in 2016.

For her PhD, Robinton researched stem cells and their therapeutical applications.[3] Her research focused on the novel technology of induced pluripotent stem cells (iPSCs), which are somatic cells reprogrammed to be stem cells and are an alternative, more ethical option to using embryonic stem cells (ESCs) in research. Her paper compares the potential uses of iPSCs vs. ESCs and fundamental differences between the two. She furthered her stem cell work by researching their applications, maintenance, metabolism, and oncogenesis.[4] Robinton worked on Lin28b, which is an RNA-binding protein that influences stem cell function in liver cancer.

Research discoveries and accomplishments

As a postdoctoral researcher at Boston Children's Hospital from 2017 to 2018, Robinton researched neurodevelopment and how cell-to-cell interactions impact neurodegenerative diseases in the lab of Beth Stevens.[5]

In more recent work, Robinton has shifted her focus on an emerging field of longevity biotechnology.[6] This field researches the mechanisms that drive natural aging and is looking to develop new theraputics to combat or slow these processes. Robinton is especially interested in the women's health aspect of longevity biotechnology and its influence on ovarian aging. Currently, she is the director of women's health at Cambrian Bio in Cambridge, Massachusetts. In addition to that role, she is the CEO and co-founder of Oviva Therapeutics,[1] which is a biotech company based in New York City conducting on going research and clinical trials in this field.[7][8]

Robinton is a scientific advisory board member at Dior,[9][10] which is exploring the field of reverse aging and its application to the beauty industry. She is also an advisory council member at SHE Media,[11] a lifestyle media company with articles ranging from health, food, and family to career and entertainment.

She was also the co-founder of Weird and Wonderful Inc.[12]

Awards and Honors

  • Bruin Business 100 (2023) - Oviva Therapeutics[13]
  • Emerging Women Founders in Bio (2021)[14]
  • Forbes 30 under 30 (2017)[2]

References

  1. 1 2 "Home". www.ovivatx.com. Retrieved 2023-11-28.
  2. 1 2 "Daisy Robinton". Forbes. Retrieved 2023-11-28.
  3. ↑ Robinton, Daisy A.; Daley, George Q. (January 2012). "The promise of induced pluripotent stem cells in research and therapy". Nature. 481 (7381): 295–305. Bibcode:2012Natur.481..295R. doi:10.1038/nature10761. PMC 3652331. PMID 22258608.
  4. ↑ Nguyen, Liem H.; Robinton, Daisy A.; Seligson, Marc T.; Wu, Linwei; Li, Lin; Rakheja, Dinesh; Comerford, Sarah A.; Ramezani, Saleh; Sun, Xiankai; Parikh, Monisha S.; Yang, Erin H.; Powers, John T.; Shinoda, Gen; Shah, Samar P.; Hammer, Robert E.; Daley, George Q.; Zhu, Hao (August 2014). "Lin28b Is Sufficient to Drive Liver Cancer and Necessary for Its Maintenance in Murine Models". Cancer Cell. 26 (2): 248–261. doi:10.1016/j.ccr.2014.06.018. PMC 4145706. PMID 25117712.
  5. ↑ Qin, Yan; Garrison, Brian S.; Ma, Wenjiang; Wang, Rui; Jiang, Aiping; Li, Jing; Mistry, Meeta; Bronson, Roderick T.; Santoro, Daria; Franco, Charlotte; Robinton, Daisy A.; Stevens, Beth; Rossi, Derrick J.; Lu, Chafen; Springer, Timothy A. (June 2018). "A Milieu Molecule for TGF-β Required for Microglia Function in the Nervous System". Cell. 174 (1): 156–171.e16. doi:10.1016/j.cell.2018.05.027. PMC 6089614. PMID 29909984.
  6. ↑ Boekstein, Nicola; Barzilai, Nir; Bertram, André; Betts-LaCroix, Joe; Fortney, Kristen; Helliwell, Stephen B.; Hufford, Michael; Mannick, Joan; McLaughlin, Jerry; Mellon, Jim; Morgen, Eric; Regge, Nils; Robinton, Daisy A.; Sinclair, David A.; Young, Sergey; Starr, Risa; Zhavoronkov, Alex; Peyer, James (August 2023). "Defining a longevity biotechnology company". Nature Biotechnology. 41 (8): 1053–1055. doi:10.1038/s41587-023-01854-0. PMID 37365260. S2CID 259259178.
  7. ↑ "Oviva Therapeutics, a Cambrian BioPharma *PipeCo, announces Seed Financing and Exclusive License with Massachusetts General Hospital to Develop Therapeutics to Extend Healthspan in Women" (Press release). Oviva Therapeutics. 19 May 2022.
  8. ↑ Oviva Therapeutics. "The woman who wants more choice around menopause". BBC.
  9. ↑ "Board members | DIOR SCIENCE: Reverse Aging". www.dior.science. Retrieved 2023-12-03.
  10. ↑ Weil, Jennifer (23 June 2023). "Dior's Scientific Advisory Board on 'Reverse-aging' Set to Meet". WWD. ProQuest 2830028928.
  11. ↑ "SHE Media". SHE Media. Retrieved 2023-12-01.
  12. ↑ "wandw". wandw.world. Retrieved 2023-12-01.
  13. ↑ "Bruin Business 100 - 2023". UCLA Alumni. Retrieved 2023-12-04.
  14. ↑ "Emerging Women Founders in Bio". The Wave Summit. Retrieved 2023-12-04.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.